Equities

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals Holding Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.5632
  • Today's Change-0.003 / -0.49%
  • Shares traded464.41k
  • 1 Year change-98.36%
  • Beta2.1380
Data delayed at least 15 minutes, as of Jul 30 2024 16:54 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include Tonmya (TNX-102 SL), TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801 and TNX-1800. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.

  • Revenue in USD (TTM)10.25m
  • Net income in USD-98.59m
  • Incorporated2007
  • Employees103.00
  • Location
    Tonix Pharmaceuticals Holding Corp26 Main Street, Suite 101CHATHAM 07928United StatesUSA
  • Phone+1 (212) 980-9155
  • Fax+1 (212) 923-5700
  • Websitehttps://www.tonixpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shuttle Pharmaceuticals Holdings Inc0.00-7.35m6.72m8.00--2.44-----0.4739-0.47390.000.16420.00----0.00-96.75---119.37-------------5.280.2542-------112.71------
Sunshine Biopharma Inc26.74m-4.09m6.89m44.00--0.0118--0.2577-13.35-13.3576.9624.960.90813.1311.58607,722.50-13.88-101.52-17.99-137.0433.1535.47-15.29-165.333.23--0.00--454.42--83.15--110.99--
Cannapharmarx Inc25.84k-6.61m7.29m21.00------282.02-0.0205-0.02050.00008-0.04250.0031--0.45031,230.48-79.52-131.06-----1,692.76---25,598.30--0.0033-0.1306--------143.24------
Vestiage Inc0.00-21.76k7.70m0.00---------0.0004-0.00040.00-0.00110.00-------4,945.46---------------------------102.30------
Lotus Pharmaceuticals Inc70.79m1.72m8.08m233.000.05420.00082.090.11420.05530.05532.563.580.632137.2717.85303,836.901.5522.841.7126.4035.1041.622.4519.930.442830.800.05160.0028.7131.70-12.2251.1170.48--
Bon Natural Life Ltd29.52m4.60m8.09m96.000.40820.06741.470.2744.994.9932.1030.230.704515.275.19307,524.6010.8614.0413.6920.6829.9430.0015.4217.622.4130.540.09550.00-1.2922.32-26.3283.09-6.70--
CV Sciences Inc15.86m-3.23m8.18m42.00--3.46--0.5157-0.0207-0.02070.10120.01451.591.4227.25377,571.40-32.43-43.42-83.71-77.7545.1351.81-20.38-45.680.2677-13.320.0472---1.24-19.80133.96-20.87----
Psyence Biomedical Ltd0.001.52m8.29m------5.47---0.0442-0.04420.00-0.39790.00------1.13--1.20-----------------------2.63------
DH Enchantment Inc680.00-156.15k8.31m1.00------12,225.15-0.0002-0.00020.00-0.00120.07150.943745.33680.00-1,641.09-------60.29---22,963.23--0.0032-13.28-----95.43--59.53------
Coeptis Therapeutics Holdings Inc0.00-16.31m9.54m5.00--2.15-----0.5804-0.58040.000.11970.00----0.00-212.70-36.90-378.58-37.81------------0.349------43.40------
Tonix Pharmaceuticals Holding Corp10.25m-98.59m9.88m103.00--0.0121--0.9638-177.41-177.419.4646.940.0652----99,514.56-62.71-59.46-70.20-65.9237.55---961.87-5,126.730.8666--0.0767------0.1874--320.57--
Silo Pharma Inc72.12k-3.53m11.08m3.00--1.32--153.59-1.18-1.200.0241.870.008----24,040.00-39.26-24.90-43.11-26.3991.9082.79-4,889.57-2,757.85----0.00--0.00--7.07------
Healthy Extracts Inc2.56m-2.76m11.23m----74.07--4.39-0.9512-0.95120.88190.05120.94280.503532.10---101.47-53.78-375.65-146.6568.4645.68-107.63-87.530.1293-2.220.879--10.41105.93-151.54------
Guardion Health Sciences Inc12.06m-5.12m12.43m9.00--3.64--1.03-4.00-4.009.492.660.97182.635.961,340,280.00-41.26-77.90-47.92-86.5543.4342.45-42.46-176.936.49-4.240.00--10.8567.03101.00---58.56--
Data as of Jul 30 2024. Currency figures normalised to Tonix Pharmaceuticals Holding Corp's reporting currency: US Dollar USD

Institutional shareholders

10.25%Per cent of shares held by top holders
HolderShares% Held
L1 Capital Global, Inc.as of 12 Jun 2024295.50k4.22%
Sabby Management LLCas of 31 Mar 2024153.00k2.19%
Empery Asset Management LPas of 31 Dec 202372.30k1.03%
Alyeska Investment Group LPas of 31 Mar 202462.50k0.89%
Marshall Wace LLPas of 31 Mar 202450.86k0.73%
Rosalind Advisors, Inc.as of 30 Jun 202428.15k0.40%
The Vanguard Group, Inc.as of 31 Mar 202416.59k0.24%
Armistice Capital LLCas of 31 Mar 202415.28k0.22%
Geode Capital Management LLCas of 31 Mar 202412.46k0.18%
Acadian Asset Management LLCas of 31 Mar 202410.48k0.15%
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.